AKTX

Akari Therapeutics Plc (AKTX) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Akari Therapeutics Plc is a pre-clinical oncology company developing next-generation antibody-drug conjugates (ADCs) anchored by its proprietary PH1 spliceosome-modulating payload. The Company has no commercial products and has not generated revenue since inception. Operations are focused on advancing the lead candidate, AKTX-101, toward IND-enabling activities and clinical trials.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Impairment Charges: The six-month 2026 operating loss increased significantly due to non-cash impairment charges totaling $12.1 million. This includes an $8.4 million goodwill impairment and a $3.7 million impairment of the AKTX-101 in-process research and development (IPR&D) asset, triggered by a decline in market capitalization.
• Increased R&D Spend: R&D expenses rose by $2.1 million year-over-year, driven by increased preclinical development activities for the ADC platform and AKTX-101.
• Financing Activity: The Company raised approximately $5.2 million in net proceeds from a May 2026 Private Placement and $3.0 million from warrant exercises during the period.
• Share Structure: The Company executed an ADS Ratio Change effective March 31, 2026, adjusting the ratio from 1 ADS = 2,000 shares to 1 ADS = 80,000 shares to regain Nasdaq compliance.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for one year following the report date. Cash of $7.8 million is insufficient to fund operations for the next 12 months. The Company projects cash sufficiency only into December 2026.
• Capital Needs: Substantial additional financing is required to fund operations and service obligations. Strategies include equity/debt offerings and strategic collaborations. Failure to secure funding could force delays in development or cessation of operations.
• Strategic Developments:
  • Initiated GMP manufacturing for AKTX-101 with WuXi Biologics/XDC, targeting Phase 1 trials by mid-2027.
  • Announced a strategic research collaboration with Whitehawk Therapeutics (July 2026) to evaluate PH1 payload technology.
  • Secured a $25 million Equity Line of Credit (ELOC) with White Lion Capital, with the registration statement declared effective in July 2026.
• Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting (IT general controls and purchase-to-pay processes) which remain unremediated as of June 30, 2026.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next financing round given the "substantial doubt" disclosure and current cash balance of $7.8 million.
• Impairment Drivers: Review the specific valuation assumptions (discount rates, probability of success) used in the $12.1 million impairment charge to assess future asset valuation risks.
• Dilution Risk: Assess the impact of the $25 million ELOC with White Lion and the outstanding warrants (over 6.9 million ADSs) on future shareholder dilution.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting controls.
• AKTX-101 Timeline: Confirm the feasibility of the projected mid-2027 Phase 1 trial start date given current funding constraints.